Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. by Millman, AL et al.
JULY JOGC JUILLET 2011  l  705
Oxygen Saturation as a Predictor of Adverse 
Maternal Outcomes in Women with Preeclampsia
Alexandra L. Millman, BSc,1 Beth Payne, BSc,1,2 Ziguang Qu, BASc,1,2 
M. Joanne Douglas, MD, FRCPC,3 Jennifer A. Hutcheon, PhD,1,2,4 Tang Lee, MSc,1,2 
Laura A. Magee, MD, FRCPC, MSc,1,2,4,5 Keith R. Walley, MD, PhD, FRCPC,5 
Peter von Dadelszen, MBChB, DPhil, FRCSC1,2,4; for the PIERS 
(Pre-eclampsia Integrated Estimate of RiSk) Study Group
1Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver BC
2The CFRI Reproduction and Healthy Pregnancy Cluster, University of British Columbia, Vancouver BC
3Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver BC
4School of Public and Population Health, University of British Columbia, Vancouver BC
5Department of Medicine, University of British Columbia, Vancouver BC
OBSTETRICS
Key Words: Preeclampsia, pregnancy, oximetry
Competing Interests: None declared .
Received on September 13, 2010
Accepted on February 24, 2011
Abstract
Objective: We sought to determine the role of respiratory 
assessment by cardiorespiratory symptoms and/or oxygen 
saturation by pulse oximetry (SpO2) in predicting adverse maternal 
outcomes in women admitted to hospital with preeclampsia .
Methods: These data derive from an international, prospective 
multicentre cohort study, PIERS (Pre-eclampsia Integrated 
Estimate of RiSk), which assesses predictors of adverse 
outcomes in women admitted to tertiary perinatal units 
with preeclampsia . Univariate and multivariate analyses of 
cardiorespiratory symptoms and pulse oximetry were performed 
to assess their ability to predict a combined adverse maternal 
outcome developed through international Delphi consensus .
Results: SpO2 successfully predicted adverse maternal outcomes; 
the area under the receiver-operator characteristic curve (AUC 
ROC) was 0 .71 (95% CI 0 .65 to 0 .77) . Combining the symptoms 
of chest pain and/or dyspnea with pulse oximetry improved this 
predictive ability (AUC ROC 0 .73; 95% CI 0 .67 to 0 .78) . When SpO2 
was stratified into risk groups using inflection points on the ROC 
curve, the highest risk group (SpO2 90% to 93%) had an odds ratio 
of 18 .1 (95% CI 8 .2 to 40 .2) for all outcomes within 48 hours when 
compared with the baseline group (SpO2 98% to 100%) .
Conclusion: Assessing SpO2 aids in the assessment of maternal risk 
in women admitted to hospital with preeclampsia . An SpO2 value 
of ≤ 93% confers particular risk . The symptom complex of chest 
pain and/or dyspnea adds to the association .
Résumé
Objectif : Nous avons cherché à déterminer le rôle de l’évaluation 
respiratoire en fonction des symptômes cardiorespiratoires  
et/ou celui de la détermination de la saturation en oxygène par 
oxymétrie pulsée (SaO2) dans la prédiction des issues maternelles 
indésirables chez les femmes hospitalisées en raison d’une 
prééclampsie .
Méthodes : Ces données sont issues de l’étude de cohorte 
multicentrique prospective internationale PIERS (Pre-eclampsia 
Integrated Estimate of RiSk), laquelle a évalué les facteurs 
prédictifs des issues indésirables chez les femmes admises dans 
des unités périnatales tertiaires en raison d’une prééclampsie . 
Des analyses univariées et multivariées des symptômes 
cardiorespiratoires et de l’oxymétrie pulsée ont été menées pour 
en évaluer la capacité de prédire une issue maternelle indésirable 
combinée, élaborée par consensus Delphi international .
Résultats : La SaO2 a permis de prédire avec succès les issues 
maternelles indésirables; la surface sous la courbe de la fonction 
d’efficacité de l’observateur-opérateur (AUC ROC) était de  
0,71 (IC à 95 %, 0,65 – 0,77) . Le fait de combiner les symptômes 
de la douleur thoracique et/ou de la dyspnée à l’oxymétrie pulsée a 
entraîné l’amélioration de cette capacité de prédiction (AUC ROC, 
0,73; IC à 95 %, 0,67 – 0,78) . Lorsque la SaO2 a été stratifiée en 
groupes de risque en fonction de points d’inflexion sur la courbe 
ROC, le groupe exposé au risque le plus élevé (SaO2 90 % - 93 %) 
présentait un rapport de cotes de 18,1 (IC à 95 %, 8,2 – 40,2) pour 
toutes les issues dans un délai de 48 heures, par comparaison 
avec le groupe de base (SaO2 98 % - 100 %) .
Conclusion : L’évaluation de la SaO2 contribue à l’évaluation du 
risque maternel chez les femmes hospitalisées en raison d’une 
prééclampsie . Une valeur de SaO2 ≤ 93 % confère un risque 
particulier . Le complexe de symptômes de la douleur thoracique 
et/ou de la dyspnée contribue à l’association .
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INTRODuCTION
Preeclampsia is a multi-organ syndrome that may be characterized by multiple symptoms, signs, and 
laboratory assessments. It is generally defined as the 
presence of  hypertension and proteinuria but can also 
involve hyperuricemia, hemolysis, liver perturbations, 
thrombocytopenia, and eclampsia. Preeclampsia remains 
the second leading global cause of  maternal mortality.1
Current classifications of  preeclampsia do not reliably 
predict adverse maternal or perinatal outcomes. The 
management of  “severe” preeclampsia, as currently 
defined, may lead to inappropriate premature delivery as 
opposed to expectant management.2,3
Measurement of  oxygen saturation by pulse oximetry is 
widely used clinically. There have been numerous studies 
with conflicting findings on the predictive value of  SpO
2
 
in adult and pediatric populations.4–9 While there are 
limited data related to a normal range in pregnancy against 
which to measure physiological perturbations, a suggested 
normal value for SpO
2
 in pregnancy is ≥ 97%.10 The ability 
of  maternal SpO
2
 to predict adverse maternal outcomes 
has been poorly studied, and in the few studies of  the 
subject the definitions of  oxygen desaturation events are 
inconsistent. Although most would agree that an SpO
2
 
< 90% constitutes an abnormal value (or hypoxemia), 
some studies of  pregnant women have used much higher 
values (up to SpO
2
 < 95%) to classify desaturations.11–14
In this study, we aimed to evaluate the predictive value 
of  SpO
2
 in pregnant women admitted to hospital with 
preeclampsia and to establish risk levels that are more 
clinically informative than the simple and traditional 
classifications of  “normal” or “hypoxic.” A secondary aim 
was to determine whether or not the symptom complex 
of  chest pain and/or dyspnea improves the discriminative 
power of  SpO
2
 in assessing women admitted to hospital 
with preeclampsia.
MATERIALS AND METHODS
For this study we used data from the PIERS database.15 
PIERS is an ongoing prospective study of  women with 
preeclampsia admitted to obstetric centres that have a 
general policy of  expectant management of  preeclampsia 
remote from term. Data were collected on women admitted 
from September 2003 until January 2010. The centres (and 
level of  neonatal intensive care) were British Columbia’s 
Women’s Hospital (level 3) and St Paul’s Hospital 
(level 1), Vancouver, BC; Surrey Memorial Hospital 
(level 2), Surrey, BC; Kingston General Hospital (level 3), 
Kingston, ON; the Ottawa Hospital’s General (level 3) and 
Civic (level 2) Campuses, Ottawa, ON; Centre Hospitalier 
Universitaire de Sherbrooke (level 3), Sherbrooke, QC; 
Christchurch Women’s Hospital (level 3), Christchurch, 
New Zealand; King Edward Memorial Hospital for 
Women (level 3), Subiaco, Western Australia; Nottingham 
City Hospital (level 3), Nottingham, United Kingdom and 
St James’s University Hospital (level 3), Leeds, United 
Kingdom. Until September 2007, women in four sites were 
required to give informed consent to be enrolled in PIERS; 
thereafter, in all but one of  the sites enrolled, PIERS was 
conducted as a continuous quality improvement project. 
Research Ethics Board approval was obtained at all sites.
The CQI project entailed the introduction of  predetermined 
guidelines for the initial assessment and ongoing 
surveillance of  women admitted to hospital with either 
suspected or confirmed preeclampsia. The details of  these 
guidelines have been previously published.16,17 Specifically, 
the guidelines recommended that oxygen assessment by 
pulse oximetry be performed once daily on the day of  
admission, on the day after admission, every subsequent 
Monday and Thursday, and on the day of  delivery. It should 
be noted that these guidelines represented the minimum 
surveillance required, and repetition of  tests in excess of  
the guidelines was at the discretion of  the clinician.
Women hospitalized with gestational hypertension were 
evaluated for their eligibility for PIERS by a research 
assistant not involved in patient care. Inclusion criteria were 
(1) blood pressure ≥ 140/90 mmHg (measured on two 
occasions at least four hours apart, after 20 weeks’ gestation) 
and either proteinuria (of  ≥ 2+ by dipstick, ≥ 0.3g/day by 
24-hour urine collection, or > 30mg/mmol by spot urinary 
protein:creatinine ratio), or hyperuricemia (greater than the 
local upper limit of  normal for non-pregnant individuals); 
(2) HELLP syndrome even in the absence of  hypertension 
or proteinuria; or (3) superimposed preeclampsia, defined 
as pre-existing hypertension with accelerated hypertension 
(as diagnosed by the clinician or defined as a systolic 
BP ≥ 170 mmHg or diastolic BP ≥ 120 mmHg), new 
ABBREVIATIONS
AUC area under the curve
BP  blood pressure
CQI  continuous quality improvement
HELLP hemolysis, elevated liver enzymes, low platelet count
PIERS Pre-eclampsia Integrated Estimate of RiSk
ROC receiver-operator characteristic
SpO2 oxygen saturation by pulse oximetry
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Table 1. Characteristics of women in the PIERS study
Characteristic
Adverse outcomes
(N = 201 women)
(N = 228 fetuses)
Normal outcomes
(N = 1333 women)
(N = 1459 fetuses)
P 
(Fisher exact or  
Mann-Whitney U)
Demographics (within 48 hrs of eligibility) Median (IQR)
Maternal age at EDD, years 31 (27 to 35) 32 (27 to 36) 0 .523
Gestational age at eligibility, weeks 34 .1 (30 .3 to 36 .7) 36 .3 (33 .4 to 38 .4) < 0 .001
n (%)
Gestational age at eligibility < 34 weeks 96 (47 .8) 380 (28 .5) < 0 .001
Multiple pregnancy 25 (12 .4) 124 (9 .3) 0 .161
Parity ≥ 1 19 (9 .5) 147 (11 .0) 0 .803
Smoking in this pregnancy 21 (10 .4) 155 (11 .6) 0 .721
Preeclampsia description < 0 .001*
Hypertension and proteinuria 137 (68 .2) 894 (67 .1)
Hypertension and hyperuricemia 18 (9 .0) 217 (16 .3)
HELLP without hypertension or proteinuria 21 (10 .4) 27 (2 .0)
Superimposed preeclampsia 25 (12 .4) 195 (14 .6)
Clinical assessments (within 48 hrs of eligibility)
Peak BP, mmHg Median (IQR)
Mean arterial pressure 125 (117 to 135) 121 (114 to 130) < 0 .001
Systolic BP 170 (158 to 184) 162 (150 to 177) < 0 .001
Diastolic BP 105 (100 to 113) 102 (98 to 110) 0 .019
Worst dipstick proteinuria 3+ (1 to 4) 2+ (1 to 3) < 0 .001
Lowest platelet concentration, × 109/L 167 (99 to 223) 191 (149 to 239) < 0 .001
Highest aspartate transaminase, IU/L 37 (26 to 97) 18 (12 to 30) < 0 .001
Lowest SpO2, % 96 (95 to 97) 97 (96 to 98) < 0 .001
Chest pain or dyspnea, n (%) 32 (15 .9) 50 (3 .8) < 0 .001
Interventions n (%)
Corticosteroid administration 82 (40 .8) 345 (25 .9) < 0 .001
Antihypertensive medications administered 161 (80 .1) 920 (69 .0) 0 .001
MgSO4 administered† 125 (62 .2) 440 (33 .0) < 0 .001
Pregnancy outcomes Median (IQR)
Admission-to-delivery interval in days, all cases 2 (1 to 4) 2 (1 to 5) 0 .612
Admission-to-delivery interval in days, < 34+0 wks 2 (1 to 6) 4 (1 to 12) 0 .001
Gestational age at delivery, weeks 34 .9 (30 .7 to 37 .0) 37 .0 (34 .4 to 38 .7) < 0 .001
Birth weight, g 1938 (1189 to 2786) 2638 (1858 to 3290) < 0 .001
n (%)
Birth weight < 3rd percentile25 18 (7 .9) 125 (8 .6) 0 .794
Intrauterine fetal death (≥ 20+0 wks and/or ≥ 500 g) 3 (1 .3) 14 (1 .0) 0 .479
Neonatal death (before 28 days of life) 5 (2 .2) 13 (0 .9) 0 .074
Infant death prior to hospital discharge or 6 weeks of age 9 (2 .6) 17 (1 .2) 0 .108
EDD: expected date of delivery; IQR: interquartile range 
* Pearson chi-square test
† According to the Magpie dosing regimen20
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proteinuria, or new hyperuricemia. Women were excluded 
if  they were admitted in active labour or if  they achieved any 
component of  the combined adverse maternal outcome 
prior to collection of  predictors. This inclusive definition 
was chosen to reflect the variable and multisystemic nature 
of  preeclampsia seen in clinical practice.
The PIERS database contains extensive data on each 
patient, including lowest daily SpO
2
 as documented in 
the patient’s chart and daily occurrence of  the combined 
cardiorespiratory symptoms of  chest pain and/or dyspnea.
The PIERS combined adverse maternal outcome was 
developed by iterative Delphi consensus (members of  
the consensus panel are listed at the PIERS website18), 
and includes maternal death and hepatic, central nervous 
system, renal, cardiorespiratory, and hematological 
morbidities.
Table 2. Adverse maternal outcomes
One or more of maternal morbidity or mortality:
Within 48 hours
n (%)
Within 7 days
n (%)
At any time
n (%)
Total adverse outcomes 94 (6 .1) 168 (11 .0) 201 (13 .1)
Total non-respiratory adverse outcomes 67 (4 .4) 114 (7 .4) 137 (8 .9)
Maternal death 0 0 0
Central nervous system
Eclampsia (≥ 1) 5 8 9
Glasgow coma score < 13 1 1 2
Stroke or reversible ischemic neurological deficit 0 0 1
Transient ischemic attack 0 1 1
Cortical blindness or retinal detachment 0 0 0
Posterior reversible encephalopathy 0 0 0
Cardiorespiratory
Positive inotropic support 0 0 1
Infusion of a 3rd parenteral antihypertensive 0 1 2
Myocardial ischemia/infarction 1 1 1
SpO2 < 90% 11 23 28
≥ 50% FiO2 for > 1hr 12 16 21
Intubation 1 4 6
Pulmonary edema 22 42 47
Hematological
Transfusion of any blood product 27 57 69
Platelet concentration < 50 × 109/L with no transfusion 20 29 29
Hepatic
Dysfunction 8 10 10
Hematoma/rupture 0 0 0
Renal
Acute renal insufficiency (serum creatinine > 150 µmol/L,  
no renal disease)
3 4 5
Acute renal failure (serum creatinine > 200 µmol/L  
with renal disease) 
3 3 3
Dialysis 0 0 1
Placental outcomes
Placental abruption 12 19 26
Other adverse events
Ascites 1 2 2
Bell’s palsy 0 0 0
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The potential for lead-time bias was addressed by 
standardizing eligibility only from hospitalization with 
preeclampsia, and not necessarily from disease onset. 
Incompetence bias (missing values and misclassification) 
was reduced by abstractor training, development and 
validation of  the Microsoft Access database, feasibility 
and development studies using that database, and random 
reabstraction of  charts. Misclassification errors were further 
minimized by database surveillance and 5% reabstraction. 
The study was pragmatic, and test reproducibility was not 
examined, consistent with clinical care; we relied on in-
house training and review for ensuring test reproducibility. 
Customized case report forms and a Microsoft Access 
database were created for data entry and used at all 
participating sites. Data were collected from the women’s 
medical records.
The value for oxygen saturation used in this study was the 
lowest SpO
2
 value recorded in each patient’s medical record 
within 48 hours after fulfilling the eligibility criteria or 
before the occurrence of  an adverse outcome, whichever 
occurred first. The dependent variables we examined 
were all dichotomous. We investigated combined adverse 
maternal outcome (defined above) within 48 hours, within 
seven days, and at any time. A second adverse outcome 
variable (non-respiratory adverse outcomes) was developed 
that excluded the adverse respiratory outcomes (pulmonary 
edema, SpO
2
 < 90%, intubation, and requirement of  
≥ 50% fraction of  inspired oxygen for more than one 
hour). For this second outcome variable, women with 
only respiratory adverse outcomes were coded as having 
a normal outcome, whereas women who experienced at 
least one non-respiratory adverse outcome were coded as 
having had an adverse outcome.
The key independent variable investigated was SpO
2
. 
This was both analyzed as a continuous variable and 
stratified into risk groups using inflection points on 
the ROC curve (baseline [98% to 100%], low risk 
[96% to 97%], medium risk [94% to 95%], and high risk 
[90% to 93%]). The dichotomous independent variable of  
cardiorespiratory symptoms (chest pain and/or dyspnea) 
was also investigated.
Each of  the independent variables (SpO
2
 and 
cardiorespiratory symptoms) was analyzed using a 
univariate logistic regression to examine any potential 
relationship with the combined adverse maternal outcome 
and non-respiratory adverse outcome within 48 hours, 
within seven days, and at any time. These independent 
variables were then combined using a multivariate logistic 
regression analysis to determine if  combining them would 
enhance the predictive power of  the model. Area under 
the curve of  the receiver-operator characteristic was 
calculated to show the relationship between true-positive 
and false-positive ratios. A minimum AUC ROC of  > 0.7 
is needed to indicate an adequately discriminative test. A 
perfectly discriminative test would have an AUC ROC of  
1.0 and a completely non-discriminative test would have 
an AUC ROC of  0.5. Odds ratios with 95% confidence 
intervals were calculated using the stratified oxygen 
saturation baseline and low, medium, and high risk groups. 
Each risk group was compared with the baseline group; 
therefore, the baseline group always had a relative risk of  
1.0. Odds ratios were calculated using a multivariate logistic 
regression with dummy variables for each risk group. All 
statistical analyses were performed using SPSS 17.0 (IBM, 
Somers NY). All figures were produced using GraphPad 
Prism 4 (GraphPad, San Diego, CA).
Table 3. univariabte analyses of independent variables by type and time of adverse outcome
Variable Outcome type Time OR (95% CI) P AUC ROC (95% CI)
Oxygen saturation All adverse outcomes 48 hrs 0 .67 (0 .61 to 0 .74) < 0 .001 0 .71 (0 .65 to 0 .77)
7 days 0 .78 (0 .72 to 0 .84) < 0 .001 0 .61 (0 .56 to 0 .66)
Any time 0 .82 (0 .76 to 0 .89) < 0 .001 0 .58 (0 .53 to 0 .62)
Non-respiratory 48 hrs 0 .77 (0 .68 to 0 .86) < 0 .001 0 .64 (0 .57 to 0 .71)
adverse outcomes
7 days 0 .87 (0 .79 to  0 .96) 0 .004 0 .57 (0 .51 to 0 .62)
Any time 0 .90 (0 .82 to 0 .99) 0 .025 0 .54 (0 .49 to 0 .59)
Chest pain and/or dyspnea All adverse outcomes 48 hrs 6 .01 (3 .45 to 10 .46) < 0 .001 0 .59 (0 .52 to 0 .65)
7 days 4 .24 (2 .61 to 7 .04) < 0 .001 0 .56 (0 .51 to 0 .61)
Any time 4 .86 (3 .03 to 7 .79) < 0 .001 0 .56 (0 .52 to 0 .61)
Non-respiratory 48 hrs 2 .17 (0 .96 to 4 .90) 0 .064 0 .53 (0 .45 to 0 .60)
adverse outcomes
7 days 1 .37 (0 .64 to 2 .93) 0 .411 0 .51 (0 .45 to 0 .57)
Any time 1 .82 (0 .96 to 3 .45) 0 .066 0 .52 (0 .47 to 0 .57)
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RESuLTS
Of  the 2023 women entered in the PIERS database 
between September 1, 2003, and January 31, 2010, 
1534 women were eligible for this study, having had an 
SpO
2
 recorded within 48 hours of  eligibility or prior to 
the occurrence of  an adverse outcome. The remaining 
489 women were excluded because they lacked an SpO
2 
value for the first 48 hours after eligibility or before the 
occurrence of  an adverse outcome. The demographics 
of  the study cohort, comparing those with any aspect 
of  the combined adverse maternal outcome at any time 
(n = 201; 13.1%) with those with normal outcomes, 
are shown in Table 1. Women who experienced adverse 
outcomes tended to have a lower gestational age, were 
more likely to have HELLP syndrome, and were less 
likely to have preeclampsia diagnosed on the basis of  
hypertension and hyperuricemia. Women with adverse 
outcomes were sicker overall; they were more hypertensive 
and more proteinuric, had higher liver enzyme levels, lower 
platelet counts, and lower SpO
2 
levels, and were more likely 
to have experienced cardiorespiratory symptoms. Women 
with adverse outcomes were also more likely to have 
had therapeutic interventions, including corticosteroids, 
antihypertensives, and magnesium sulphate. These women 
also delivered babies with lower birth weights at earlier 
gestational ages, but there was no statistically significant 
increase in perinatal or infant mortality.
The outcomes experienced by women in this study are 
shown in Table 2. A total of  201 women (13.1%) experienced 
at least one component of  the combined adverse maternal 
outcome at some time. The most common outcomes 
were pulmonary edema (47, 3.1%) and blood transfusion 
(69, 4.5%). Of  the 201 women, 137 (8.9%) experienced 
one or more non-respiratory components of  the adverse 
maternal outcome.
Univariate logistic regression coefficients were significant 
for both SpO
2
 and cardiorespiratory symptoms for 
prediction of  “all outcomes” at any time (P < 0.001) 
(Table 3). The AUC ROC for SpO
2
 alone was 0.71 
(95% CI 0.65 to 0.77) for predicting adverse maternal 
outcomes within 48 hours (Table 3). The multivariate 
regression analysis for SpO
2
 and cardiorespiratory 
symptoms is presented in Table 4, and the final predictive 
equation for all outcomes within 48 hours is
logit (p) = ln(p/1-p) = 31.86 – 0.362* 
(oxygen saturation) + 1.404* (cardiorespiratory symptoms)
The AUC ROC for this model is 0.73 (95% CI 0.67 to 
0.78) (Figure 1). The predicted probabilities of  adverse 
outcome based on this model are shown in Figure 2. It is 
clear that the addition of  cardiorespiratory symptoms adds 
to the discriminative power of  the model.
A sensitivity analysis was performed to assess the strength 
of  SpO
2
 and cardiorespiratory symptoms in predicting non-
respiratory adverse outcomes. SpO
2
 performed less well in 
predicting non-respiratory adverse outcomes only (regression 
coefficient −0.267, P < 0.001; AUC ROC 0.64 [95% CI 0.57 
to 0.71]) (Table 3). Cardiorespiratory symptoms were not 
predictive of  non-respiratory adverse outcomes by univariate 
logistic regression (regression coefficient 0.74, P = 0.08) or 
when combined with oxygen saturation (regression coefficient 
0.36, P = 0.41) (data not shown).
Inflection points from the ROC curve of  SpO
2
 predicting 
any adverse outcomes within 48 hours were used to 
stratify the risk of  SpO
2
 from 90% to 100%, inclusive. 
Four inflection points were identified representing oxygen 
saturations of  93.5%, 95.5%, 97.5%, and 98.5% (Figure 3). 
Therefore, 98% to 100% was defined as baseline, 96% to 
97% as low risk, 94% to 95% as medium risk, and 90% to 
93% as high risk. The odds of  any adverse outcome within 
48 hours in the high-risk group was 18-fold higher than 
in the baseline group (P < 0. 001) (Table 5). Additionally, 
the high-risk group had higher odds of  non-respiratory 
adverse outcomes within 48 hours than the baseline group 
(P < 0.001) (Table 5). At 48 hours, the odds of  “all adverse 
outcomes” were significantly higher in all risk groups (low, 
medium, high) than in the baseline group. As the interval 
between eligibility and adverse outcome increased, the OR 
decreased and became less significant. However, the high-
risk group had significantly higher odds ratios for both all 
adverse outcomes (P < 0.001) and non-respiratory adverse 
outcomes (P < 0.01 to P < 0.001) across all time points. 
Table 4. Multivariable logistic regression analysis predicting adverse maternal outcomes 
within 48 hours of admission based on SpO2 and respiratory symptoms
Predictor β-coefficient (95% CI) P OR (95% CI)
Cardiorespiratory symptoms 1 .404 (0 .802 to 2 .006) < 0 .001 4 .07 (2 .23 to 7 .43)
SpO2 −0 .362 (−0 .464 to −0 .260) < 0 .001 0 .70 (0 .63 to 0 .77)
Constant 31 .861 (22 .222 to 41 .500) < 0 .001 Not applicable
logit p_ i = ln 1 p
p
= 31.86- 0.362 # oxygen saturation+
1.404 # cardiorespiratory symptoms
−
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Chi-square for trend tests were significant across all time 
points and for both adverse outcome variables (data not 
shown).
It should be noted that maternal SpO
2
 was not predictive 
of  perinatal outcomes (data not shown).
DISCuSSION
Our findings suggest that maternal SpO
2
 usefully predicts 
adverse maternal outcomes in women admitted to hospital 
with preeclampsia. SpO
2
 was best at prediction of  any 
adverse maternal outcome within 48 hours, especially when 
combined with cardiorespiratory symptoms (AUC ROC 
0.73). The variables used in analysis were collected within 
48 hours of  eligibility (and before outcome occurrence), 
so it is logical to conclude that SpO
2
 predicts adverse 
outcomes within the same time. However, SpO
2
 within the 
first 48 hours remained predictive of  adverse outcomes 
within seven days and at any time.
The study also revealed that SpO
2
 of  90% to 93% was 
independently associated with an 18-fold increase in the 
odds of  an adverse outcome within 48 hours compared 
with a normal SpO
2
 (98% to 100%).
In preeclampsia, hypoxemia may result from a number 
of  mechanisms. Pulmonary vasospasm and inflammation 
may result in decreased pulmonary vascular perfusion 
and a ventilation-perfusion mismatch. The combined 
effects of  hypoalbuminemia, which leads to decreased 
oncotic pressure, and endothelial dysfunction, which 
increases permeability of  the pulmonary vasculature, may 
result in non-cardiogenic pulmonary edema and impaired 
pulmonary diffusion capacity. A less common mechanism 
is hypoventilation resulting from central nervous system 
complications (and obtundation) or magnesium toxicity.19
Because we expected SpO
2
 to be predictive of  respiratory 
adverse outcomes such as pulmonary edema, we additionally 
examined the generalizability of  the predictive power of  
SpO
2
 by performing a sensitivity analysis examining its 
relationship with non-respiratory adverse outcomes. The 
Table 5. Odds ratios (95% CI) of adverse outcome according to SpO2 risk group
Risk group (SpO2) All adverse outcomes Non-respiratory adverse outcomes
Adverse outcome within 48 hrs 
High risk (90 to 93%) 18 .10 (8 .15 to 40 .18)*** 6 .99 (2 .86 to 17 .10)***
Medium risk (94 to 95%) 4 .82 (2 .27 to 10 .65)*** 3 .30 (1 .46 to 7 .46)**
Low risk (96 to 97%) 2 .54 (1 .20 to 5 .35)* 2 .14 (1 .00 to 4 .57)
Adverse outcome within 7 days
High risk (90 to 93%) 5 .89 (3 .41 to 10 .15)*** 3 .15 (1 .59 to 6 .22)**
Medium risk (94 to 95%) 1 .71 (1 .05 to 2 .80)* 1 .56 (0 .88 to 2 .80)
Low risk (96 to 97%) 1 .27 (0 .83 to 1 .96) 1 .37 (0 .84 to 2 .25)
Adverse outcome at any time
High risk (90 to 93%) 4 .46 (2 .67 to 7 .43)*** 2 .55 (1 .36 to 4 .77)**
Medium risk (94 to 95%) 1 .22 (0 .78 to 1 .93) 1 .14 (0 .67 to 1 .95)
Low risk (96 to 97%) 1 .13 (0 .77 to 1 .64) 1 .17 (0 .76 to 1 .80)
All odds ratios are compared with a baseline SpO2 of 98% to 100% using multivariate logistic regression; 
P values were calculated using Wald’s chi-square .
*P < 0 .05; **P < 0 .01; ***P < 0 .001) .
Figure 1. Area under the curve of the receiver-
operator characteristic for the ability of SpO2 and 
cardiorespiratory symptoms combined to predict all 
outcomes within 48 hours
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AUC ROC for SpO
2
 was only 0.64 for prediction of  non-
respiratory adverse outcomes within 48 hours. However, 
stratified pulse oximetry was significantly associated with 
risk of  non-respiratory adverse outcomes within 48 hours 
(OR 6.99 for SpO
2
 90% to 93% compared with SpO
2
 
98% to 100%). Increased odds of  adverse outcome in 
the high-risk group (SpO
2
 90 to 93%) were statistically 
significant for all time periods (48 hours, 7 days, and any 
time) and for all adverse outcome groups (all outcomes 
and non-respiratory outcomes).
To our knowledge, this is the first study of  maternal pulse 
oximetry as a predictor of  adverse maternal outcome in 
women with preeclampsia. Our multicentre prospective 
study of  women admitted with preeclampsia features a 
large international sample (n = 1534).
We investigated whether or not treatment with magnesium 
sulphate may confound the findings of  this study. 
Magnesium sulphate was administered according to the 
Magpie regimen20 to 62.2% of  women who developed 
an adverse outcome and to 33.0% of  those who did not. 
However, rather than magnesium sulphate being on the 
causative pathway to outcome, we believe that the sicker 
women who therefore went on to develop an adverse 
outcome were also the women who were more likely to 
receive magnesium sulphate. In order to prevent over-
reporting of  adverse outcomes resulting from the side 
effects of  magnesium sulphate use, this study used a 
Glasgow Coma Scale score of  < 13 (rather than < 15) 
as the criterion for adverse outcome to account for the 
drowsiness associated with magnesium sulphate use. 
In examining the relationship between preeclampsia, 
magnesium sulphate, and SpO
2
, Thorp et al.13 did not 
find a higher risk of  oxygen desaturation in women with 
preeclampsia than in women receiving magnesium sulphate 
for other reasons; SpO
2
 < 90% was used as the definition 
of  oxygen desaturation.The major weakness of  this study 
is that 489 women (25%) in the PIERS database were 
excluded because they did not have SpO
2
 recorded within 
48 hours of  eligibility and before occurrence of  an adverse 
outcome, yet 60 of  these women (12.3%) experienced one 
or more components of  the combined adverse maternal 
Figure 2. (A) Predicted probability of outcome by multivariate logistic regression showing the difference in 
probability of outcome with or without cardiorespiratory symptoms. (B) Predicted probability of outcome by 
univariate logistic regression comparing probability for all outcomes and for non-respiratory outcomes
Figure 3. Inflection points on the area under the 
receiver-operator characteristic curve of SpO2 alone 
predicting all outcomes within 48 hours. Arrowheads 
(◄) indicate the inflection points identified.
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outcome. This lack of  compliance with the PIERS study 
protocol may be indicative of  selection bias, with sicker 
women being selected for SpO
2
 monitoring, but the 
outcome incidence was not significantly different between 
groups; 12.3% of  excluded women had an adverse outcome, 
compared with the 13.1% adverse outcome rate observed 
in the women under study (P = 0.688). Alternatively, it may 
reflect random deviation from the protocol and overall 
lower levels of  monitoring in the early stages of  the study; 
26.5% of  women were excluded from the development 
database, whereas only 20.3% were excluded from the 
validation database (P < 0.002).
A second limitation of  the study is that we included 
women with hyperuricemic, non-proteinuric hypertension 
in our cohort. However, the inclusion of  these women 
is consistent with the additional risks surrounding 
hyperuricemia21 and with our wider aim of  developing a 
generalizable model.
The recording of  only the lowest oxygen saturation 
within 48 hours represents a third weakness of  this study. 
Possible false readings from the pulse oximeter were not 
addressed. However, such events would be expected to 
occur at random, and would not be associated with women 
more likely to develop an adverse outcome. Furthermore, 
differences in training in pulse oximetry use between care 
providers were not specifically addressed, as this was an 
observational rather than an interventional study.
An SpO
2
 level < 90% is considered to be abnormal or 
representative of  hypoxemia.13,14 In the current study, 
and supported by our Delphi consensus group, SpO
2
 
< 90% was a component of  the combined adverse 
maternal outcome. As the PIERS study aims to predict 
outcomes, only the pulse oximetry readings before an 
adverse outcome were used and, therefore, there are no 
values for SpO
2
 < 90% in the PIERS database. This may 
represent a limitation of  our study in that we were unable 
to evaluate the role of  pulse oximetry readings below 90% 
in predicting other adverse outcomes. However, there 
have been no standardized cut-off  points for describing 
abnormal values in pregnant women. Previous studies 
have used SpO
2 
values of  < 90%, < 94%, and/or < 95% 
as their cut-off  points in the evaluation of  SpO
2.
11–13 The 
results presented show a clear trend of  increasing risk for 
adverse outcome with decreasing SpO
2
; this trend probably 
continues below the current data range. It is evident that 
for pregnant women the use of  only one cut-off  point is 
probably an oversimplification, and SpO
2
 can be stratified 
into groups with variable degrees of  risk. Also, the SpO
2
 
value we used as the baseline or normal range for pregnant 
women (≥ 98%) is higher than previously reported.22
The clinical syndrome of  preeclampsia can have a very rapid 
onset, with seemingly healthy women deteriorating quickly. 
Preeclampsia is linked with serious maternal comorbidities, 
including pulmonary edema and acute respiratory distress 
syndrome.23–25 Both of  these complications may result 
in decreased blood gas exchange across the alveoli, with 
consequent hypoxemia. While maternal blood gas testing is 
important for the diagnosis of  hypoxemia, it is expensive, 
invasive, painful, and slow, whereas SpO
2
 is cheap, quick, 
and non-invasive. Respiratory rate, which is the other 
bedside method for evaluating possible respiratory distress, 
is poorly assessed and recorded.26 Therefore, SpO
2
 is a 
strong candidate for use as a screening tool.9
Our data were limited to inpatient women who had 
pregnancies complicated by preeclampsia, albeit broadly and 
pragmatically defined. It will be important to assess the role 
of  pulse oximetry in outpatient women with preeclampsia, as 
well as in women whose pregnancies have been complicated 
by the other hypertensive disorders of  pregnancy (i.e., pre-
existing and non-proteinuric gestational hypertension).15 
Further research is also indicated to test whether a change in 
SpO
2
, or in the rate of  change, might usefully predict adverse 
maternal outcome in women with preeclampsia. The present 
study was limited to recording only the lowest daily SpO
2
.
How measurements of  SpO
2
 correlate with adverse 
outcomes in a multivariable regression model, to further 
clarify their role in the care of  women suffering from a 
complex and highly variable clinical syndrome, has been 
assessed in the development and validation of  the full 
PIERS model.15
CONCLuSION
We have determined that assessing SpO
2
 by pulse oximetry 
aids in the assessment of  maternal risk in women admitted 
to hospital with preeclampsia. An SpO
2
 value ≤ 93% 
confers particular risk. The symptom complex of  chest 
pain and/or dyspnea adds some strength to the association.
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